Hikma Pharmaceuticals, the fast growing multinational company in the Middle East region, announced the inauguration of Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria. The Algerian pharmaceutical company is Hikmas second venture in Algeria after Hikma Pharma, Algeria.
A press conference was held in Algiers to announce the opening of Al Dar Al Arabia Pharmaceutical Manufacturing Company as a production facility abiding by the conditions and standards of the international Good Manufacturing Practices (GMPs). The opening took place on October 18th 2011 under the patronage of, His Excellency Dr. Jamal Wild Abbass, Algerian Minister of Health and Hospitals Reform.
The pharmaceutical company announced the completion of the first phase of construction that comprises a 5850 square meter unit that will specialise in penicillin manufacturing. The unit features the latest and most innovative equipment to ensure top quality production from leading international companies, in many dosage forms such as dry suspension, capsules, pills and infusion bags.
Hikma Pharmaceuticals Executive Vice Chairman and CEO of the MENA region Mr. Mazen Darwazah stated, We at Hikma are extremely proud of what we have achieved in terms of the expansion of our facilities in Algeria. We are keen to develop Al Dar Al Arabia Pharmaceutical Manufacturing Companys work in the pharmaceutical industry while also providing the latest tools and technology to ensure superior quality in the manufacturing process.
Hikma Pharmaceuticals is looking to increase its share in the Algerian market by inaugurating the penicillin factory, which will further enable Hikma to focus on local production and better compete in the local market. In line with the Protectionism measures in Algeria that encourage the use of locally manufactured medications, this penicillin factory will undoubtedly promote local production and raise the bar for competition.
Hikma Pharma ranked second in 2011 among Algerias pharmaceutical companies in terms of sales, with a market share of 6.1%. Hikma has provided over 450 job opportunities since they joined the Algerian market in 2006, and they are providing high quality pharmaceutical products to serve the local community and support the local market.
-Ends-
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non?branded generic and in licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2010, Hikma achieved revenues of 731 million and profit attributable to shareholders of $99 million. As of December 2010, Hikma had 5,396 employees.
For news and other information, please visit www.hikma.com
FTI Consulting
Name: Manash Bhuyan
Email: manash.bhuyan@fticonsulting.com
Tel: (+971) 4 332 8832
Fax:(+971) 4 332 8388
HIKMA Pharmaceuticals
Name: Hana Ramadan,
Hala Khayyat
Email: ramadanh@Hikma.com ,
hkhayyat@Hikma.com
Tel: Hana Ramadan (+962) 6 5802900 Ext. 313
Tel: Hala Khayyat (+962) 6 5802900 Ext. 311
Press Release 2011
